Objective: Ovarian tissue cryopreservation is the only viable approach for preserving fertility in prepubertal females undergoing gonadotoxic treatment such as cyclophosphamide. The aim of this study is to assess the approaches for creating cyclophosphamide-induced premature ovarian failure models in rabbits, to determine the optimum way, and to produce a better acceptable experimental model for future study on premature ovarian failure. Method: Ten adult female rabbits were randomly allocated into two groups; 5 rabbits as control group without any treatment whereas a unilateral ovariectomy was performed. The other group (experiment and Sham) include 5 rabbits performed a unilateral ovariectomy as well, the resected ovaries cryopreserved immediately to determine the freeze-thaw damage, and animals were administered 50 mg/kg cyclophosphamide intraperitoneally as a loading dose after wound healing. The weight of the rabbits' bodies and ovaries was assessed for each group. H&E staining was used to evaluate topological alterations in ovarian follicles, and the number of normal follicles were measured and evaluated. ELISA was utilized to identify alterations in the serum concentrations of AMH and progesterone. Result: Weight loss was observed after cyclophosphamide application in the experimental group, when the experimental groups were compared with the control/sham groups, it was shown that the follicle reserve decreased statistically significantly (p<0.001). Conversely, there was no considerable difference in the ratios of abnormal primordial follicles between sham and control groups (p=0.0602). The levels of AMH and Progesterone serum concentrations in rabbits that were given cyclophosphamide were significantly lower than in the control group. Conclusion: Treatment with 50 mg/kg cyclophosphamide intraperitoneally once daily for 14 days is the most appropriate approach for establishing a rabbit model of premature ovarian failure (POF) along with assessing its effectiveness for elucidating the pathophysiological pathways underlying the disease's development and examine the potential protective and therapeutic option for POF. ORCID NO: 0000-0002-7402-4529
Anahtar Kelimeler: Premature Ovarian Failure, Cyclophosphamide, Cryopreservation, Experimental Model
|
